{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:22:42Z","timestamp":1791411762615,"version":"4.3.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Incretin analogues, used for the treatment of type 2 diabetes mellitus and obesity, such as GLP1-receptor agonist liraglutide (Lira) have been shown to reduce major adverse cardiac events in recent clinical trials of heart failure. Tirzepatide (TZP), a dual GIP\/GLP1-receptor agonist has shown promising results in the SUMMIT trial as improved cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF). However, data regarding their use in heart failure with reduced ejection fraction (HFrEF) is lacking. We performed a head-to-head comparative study in a mouse model of non-ischaemic cardiac injury induced by continuous angiotensin II (AngII) infusion, as AngII is a key driver of both heart failure forms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5\u00a0mg\/kg\/day) in 5-month-old male Balb\/c mice or sham surgery was performed. Animals were treated with vehicle (Veh), Lira (300\u00a0\u00b5g\/day i.p.) or TZP (48\u00a0\u00b5g\/day s.c.) for 14\u00a0days in the following groups: Sham\/Veh (n\u2009=\u20097), AngII\/Veh (n\u2009=\u200915), Sham\/Lira (n\u2009=\u20097), AngII\/Lira (n\u2009=\u200915), Sham\/TZP (n\u2009=\u20098), AngII\/TZP (n\u2009=\u200915). Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Mortality was significantly higher in AngII\/Veh animals compared to controls, while AngII\/TZP mice showed significantly reduced mortality after 14 days of treatment. Both Lira and TZP caused significant weight reduction compared to controls. AngII given alone also reduced body mass, and this reduction was further enhanced by TZP. Treatment with both compounds preserved cardiac systolic and diastolic function compared with AngII\/Veh animals, as shown by normal ejection fraction and E\/e\u2019, respectively. Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including <jats:italic>Ctgf, Col1a1, Col3a1,<\/jats:italic> and <jats:italic>Nppa,<\/jats:italic> while TZP also reduced the elevated <jats:italic>Nppb<\/jats:italic> level. TZP also reduced systemic inflammation, as shown by the reduction in serum CRP levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Lira and TZP preserved cardiac function and decreased markers of hypertrophy and fibrosis in mice with AngII-induced heart failure, whereas TZP also significantly decreased mortality. In addition to HFpEF, the use of incretin analogues may also be of clinical relevance in the treatment of HFrEF. However, as patients with heart failure, AngII level is elevated and can cause weight loss\/cachexia, the usage of incretin analogues to treat non-obese heart failure patients should be considered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12933-025-02806-5","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T07:43:28Z","timestamp":1749887008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tirzepatide, a dual GIP\/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide"],"prefix":"10.1186","volume":"24","author":[{"given":"Zsombor I.","family":"Heged\u0171s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rk E.","family":"Jakab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s G.","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil V.","family":"Sayour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ra","family":"Antal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n V.","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikt\u00f3ria E.","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"2806_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","volume":"229","author":"DH Ryan","year":"2020","unstructured":"Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61\u20139.","journal-title":"Am Heart J"},{"issue":"39","key":"2806_CR2","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"10454","key":"2806_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0140-6736(24)01598-8","volume":"404","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M. GLP-1 receptor agonists in heart failure. Lancet. 2024;404(10454):727\u20139.","journal-title":"Lancet"},{"issue":"15","key":"2806_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"12","key":"2806_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"5","key":"2806_CR6","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500.","journal-title":"JAMA"},{"issue":"1","key":"2806_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, H\u00e4nselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes ( LIVE )\u2014a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69\u201377.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2806_CR8","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","volume":"29","author":"JS Neves","year":"2023","unstructured":"Neves JS, Packer M, Ferreira JP. Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials. J Card Fail. 2023;29(7):1107\u20139.","journal-title":"J Card Fail"},{"issue":"3","key":"2806_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2174\/1573399816999200821164129","volume":"17","author":"F Hamad","year":"2021","unstructured":"Hamad F, Elnour AA, Elamin A, Mohamed S, Yousif I, Don J, et al. Systematic review of glucagon-like peptide one receptor agonist liraglutide of subjects with heart failure with reduced left ventricular ejection fraction. CDR. 2021;17(3):280\u201392.","journal-title":"CDR"},{"issue":"1","key":"2806_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-020-01088-3","volume":"19","author":"B Liang","year":"2020","unstructured":"Liang B, Gu N. Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE. Cardiovasc Diabetol. 2020;19(1):106.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2806_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"3","key":"2806_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s12020-019-02081-x","volume":"66","author":"S Sha","year":"2019","unstructured":"Sha S, Liu X, Zhao R, Qing L, He Q, Sun L, et al. Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice. Endocrine. 2019;66(3):494\u2013502.","journal-title":"Endocrine"},{"issue":"6","key":"2806_CR13","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","volume":"36","author":"M Ben Nasr","year":"2024","unstructured":"Ben Nasr M, Usuelli V, Dellepiane S, Seelam AJ, Fiorentino TV, D\u2019Addio F, et al. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab. 2024;36(6):1302-1319.e12.","journal-title":"Cell Metab"},{"key":"2806_CR14","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2147\/DDDT.S213910","volume":"13","author":"RH Zheng","year":"2019","unstructured":"Zheng RH, Bai XJ, Zhang WW, Wang J, Bai F, Yan CP, et al. Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats. DDDT. 2019;13:2745\u201357.","journal-title":"DDDT"},{"issue":"3","key":"2806_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10741-022-10238-6","volume":"28","author":"A Palazzuoli","year":"2022","unstructured":"Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. 2022;28(3):585\u201396.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"2806_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ehf2.15031","volume":"12","author":"NV Sayour","year":"2025","unstructured":"Sayour NV, Gergely TG, V\u00e1radi B, T\u00f3th V\u00c9, \u00c1gg B, Kov\u00e1cs T, et al. Comparison of mouse models of heart failure with reduced ejection fraction. ESC Heart Failure. 2025;12(1):87\u2013100.","journal-title":"ESC Heart Failure"},{"key":"2806_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110311","volume":"120","author":"Q Liu","year":"2023","unstructured":"Liu Q, Zhu J, Kong B, Shuai W, Huang H. Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4\/NF-kB\/NLRP3 pathway. Int Immunopharmacol. 2023;120: 110311.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"2806_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10557-023-07456-x","volume":"38","author":"X Zhao","year":"2024","unstructured":"Zhao X, Cheng Z, Zhang H, Guo Y, Zhao L, Zhang C, et al. Glucagon-like peptide-1 inhibits the progression of abdominal aortic aneurysm in mice: the earlier, the better. Cardiovasc Drugs Ther. 2024;38(5):873\u201384.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"2806_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00395-024-01088-4","volume":"120","author":"NV Sayour","year":"2024","unstructured":"Sayour NV, Kucsera D, Alhaddad AR, T\u00f3th V\u00c9, Gergely TG, Kov\u00e1cs T, et al. Effects of sex and obesity on immune checkpoint inhibition-related cardiac systolic dysfunction in aged mice. Basic Res Cardiol. 2024;120(1):207\u201323.","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"2806_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","volume":"57","author":"RB Devereux","year":"1986","unstructured":"Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450\u20138.","journal-title":"Am J Cardiol"},{"issue":"1","key":"2806_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/cvr\/cvaa110","volume":"117","author":"S Zacchigna","year":"2021","unstructured":"Zacchigna S, Paldino A, Falc\u00e3o-Pires I, Daskalopoulos EP, Dal Ferro M, Vodret S, et al. Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC working group on myocardial function. Cardiovasc Res. 2021;117(1):43\u201359.","journal-title":"Cardiovasc Res"},{"key":"2806_CR22","first-page":"15155","volume":"13","author":"TG Gergely","year":"2024","unstructured":"Gergely TG, Kov\u00e1cs T, Kov\u00e1cs A, T\u00f3th VE, Sayour NV, M\u00f3rotz GM, et al. CardiLect: a combined cross-species lectin histochemistry protocol for the automated analysis of cardiac remodelling. ESC Heart Failure. 2024;13:15155.","journal-title":"ESC Heart Failure."},{"issue":"18","key":"2806_CR23","doi-asserted-by":"publisher","first-page":"13826","DOI":"10.3390\/ijms241813826","volume":"24","author":"NV Sayour","year":"2023","unstructured":"Sayour NV, T\u00f3th V\u00c9, Nagy RN, V\u00f6r\u00f6s I, Gergely TG, On\u00f3di Z, et al. Droplet digital PCR is a novel screening method identifying potential cardiac G-protein-coupled receptors as candidate pharmacological targets in a rat model of pressure-overload-induced cardiac dysfunction. IJMS. 2023;24(18):13826.","journal-title":"IJMS"},{"issue":"9","key":"2806_CR24","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","volume":"117","author":"C Withaar","year":"2021","unstructured":"Withaar C, Meems LMG, Markousis-Mavrogenis G, Boogerd CJ, Sillj\u00e9 HHW, Schouten EM, et al. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovasc Res. 2021;117(9):2108\u201324.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"2806_CR25","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1111\/dom.15820","volume":"26","author":"PH Reis-Barbosa","year":"2024","unstructured":"Reis-Barbosa PH, Marcondes-de-Castro I, Marinho TS, Aguila MB, Mandarim-de-Lacerda CA. The dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice. Diabetes Obesity Metabol. 2024;26(10):4613\u201321.","journal-title":"Diabetes Obesity Metabol"},{"issue":"4","key":"2806_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41569-020-00465-5","volume":"18","author":"ACT Ng","year":"2021","unstructured":"Ng ACT, Delgado V, Borlaug BA, Bax JJ. Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. Nat Rev Cardiol. 2021;18(4):291\u2013304.","journal-title":"Nat Rev Cardiol"},{"issue":"19","key":"2806_CR27","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","volume":"34","author":"FP Brouwers","year":"2013","unstructured":"Brouwers FP, De Boer RA, Van Der Harst P, Voors AA, Gansevoort RT, Bakker SJ, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34(19):1424\u201331.","journal-title":"Eur Heart J"},{"issue":"18","key":"2806_CR28","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","volume":"118","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023;118(18):3434\u201350.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2806_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/dom.14862","volume":"25","author":"JS Neves","year":"2023","unstructured":"Neves JS, Vasques-N\u00f3voa F, Borges-Canha M, Leite AR, Sharma A, Carvalho D, et al. Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial. Diabetes Obesity Metabol. 2023;25(1):189\u201397.","journal-title":"Diabetes Obesity Metabol"},{"issue":"5","key":"2806_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004885","volume":"4","author":"A Jorsal","year":"2014","unstructured":"Jorsal A, Wiggers H, Holmager P, Nilsson B, Nielsen R, Boesgaard TW, et al. A protocol for a randomised, double-blind, placebo-controlled study of the effect of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes (the LIVE study). BMJ Open. 2014;4(5): e004885.","journal-title":"BMJ Open"},{"issue":"4","key":"2806_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10","key":"2806_CR32","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","volume":"151","author":"MR Zile","year":"2025","unstructured":"Zile MR, Borlaug BA, Kramer CM, Baum SJ, Litwin SE, Menon V, Ou Y, Weerakkody GJ, Hurt KC, Kanu C, Murakami M. Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity. Circulation. 2025;151(10):656\u201368.","journal-title":"Circulation"},{"issue":"10","key":"2806_CR33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fphar.2019.00537","volume":"5","author":"R Li","year":"2019","unstructured":"Li R, Shan Y, Gao L, Wang X, Wang X, Wang F. The Glp-1 analog liraglutide protects against angiotensin ii and pressure overload-induced cardiac hypertrophy via PI3K\/Akt1 and AMPKa signaling. Front Pharmacol. 2019;5(10):537.","journal-title":"Front Pharmacol"},{"issue":"14","key":"2806_CR34","first-page":"4648","volume":"22","author":"DD Huang","year":"2018","unstructured":"Huang DD, Huang HF, Yang Q, Chen XQ. Liraglutide improves myocardial fibrosis after myocardial infarction through inhibition of CTGF by activating cAMP in mice. Eur Rev Med Pharmacol Sci. 2018;22(14):4648\u201356.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"2806_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12933-024-02203-4","volume":"23","author":"F Taktaz","year":"2024","unstructured":"Taktaz F, Scisciola L, Fontanella RA, Pesapane A, Ghosh P, Franzese M, et al. Evidence that tirzepatide protects against diabetes-related cardiac damages. Cardiovasc Diabetol. 2024;23(1):112.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2806_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","volume":"85","author":"CM Kramer","year":"2025","unstructured":"Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure. J Am Coll Cardiol. 2025;85(7):699\u2013706.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2806_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCHEARTFAILURE.114.001893","volume":"8","author":"C Duerrschmid","year":"2015","unstructured":"Duerrschmid C, Trial J, Wang Y, Entman ML, Haudek SB. Tumor necrosis factor: a mechanistic link between angiotensin-II\u2013induced cardiac inflammation and fibrosis. Circ Heart Failure. 2015;8(2):352\u201361.","journal-title":"Circ Heart Failure."},{"issue":"6","key":"2806_CR38","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1161\/01.RES.72.6.1245","volume":"72","author":"W Schorb","year":"1993","unstructured":"Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res. 1993;72(6):1245\u201354.","journal-title":"Circ Res"},{"issue":"17","key":"2806_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","volume":"5","author":"FS Willard","year":"2020","unstructured":"Willard FS, Douros JD, Gabe MBN, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17): e140532.","journal-title":"JCI Insight"},{"issue":"1\u20132","key":"2806_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","volume":"1","author":"Y Seino","year":"2010","unstructured":"Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabet Invest. 2010;1(1\u20132):8\u201323.","journal-title":"J Diabet Invest"},{"key":"2806_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170228","volume":"125","author":"AA Greenwell","year":"2020","unstructured":"Greenwell AA, Chahade JJ, Ussher JR. Cardiovascular biology of the GIP receptor. Peptides. 2020;125: 170228.","journal-title":"Peptides"},{"issue":"9","key":"2806_CR42","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1253\/circj.CJ-16-0152","volume":"80","author":"M Hiromura","year":"2016","unstructured":"Hiromura M, Mori Y, Kohashi K, Terasaki M, Shinmura K, Negoro T, et al. Suppressive effects of glucose-dependent insulinotropic polypeptide on cardiac hypertrophy and fibrosis in angiotensin ii-infused mouse models. Circ J. 2016;80(9):1988\u201397.","journal-title":"Circ J"},{"issue":"1","key":"2806_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/osp4.84","volume":"3","author":"A Mehta","year":"2017","unstructured":"Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3\u201314.","journal-title":"Obes Sci Pract"},{"issue":"3","key":"2806_CR44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/dom.16106","volume":"27","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Zhu H, Gong F. Why does GLP -1 agonist combined with GIP and\/or GCG agonist have greater weight loss effect than GLP\u20141 agonist alone in obese adults without type 2 diabetes? Diabet Obesity Metabol. 2025;27(3):1079\u201395.","journal-title":"Diabet Obesity Metabol"},{"issue":"20","key":"2806_CR45","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA. 2023;330(20):2000.","journal-title":"JAMA"},{"issue":"5","key":"2806_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa020245","volume":"347","author":"S Kenchaiah","year":"2002","unstructured":"Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"2806_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/jcm14010139","volume":"14","author":"F B\u00e1nfi-Bacs\u00e1rdi","year":"2024","unstructured":"B\u00e1nfi-Bacs\u00e1rdi F, Kazay \u00c1, Gergely TG, Forrai Z, F\u00fczesi TP, Hanuska LF, et al. Therapeutic consequences and prognostic impact of multimorbidity in heart failure: time to act. JCM. 2024;14(1):139.","journal-title":"JCM"},{"issue":"1","key":"2806_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ahj.2008.02.014","volume":"156","author":"A Oreopoulos","year":"2008","unstructured":"Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156(1):13\u201322.","journal-title":"Am Heart J"},{"issue":"9","key":"2806_CR49","first-page":"1509","volume":"12","author":"AR Vest","year":"2024","unstructured":"Vest AR, Schauer PR, Rodgers JE, Sanderson E, LaChute CL, Seltz J, Lavie CJ, Mandras SA, Tang WW, daSilva-deAbreu A. Obesity and weight loss strategies for patients with heart failure. Heart Failure. 2024;12(9):1509\u201327.","journal-title":"Heart Failure"},{"issue":"13","key":"2806_CR50","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","volume":"44","author":"JH Butt","year":"2023","unstructured":"Butt JH, Petrie MC, Jhund PS, Sattar N, Desai AS, K\u00f8ber L, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023;44(13):1136\u201353.","journal-title":"Eur Heart J"},{"key":"2806_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156057","volume":"161","author":"K Stefanakis","year":"2024","unstructured":"Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism. 2024;161: 156057.","journal-title":"Metabolism"},{"issue":"1","key":"2806_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-025-02639-2","volume":"24","author":"K Shi","year":"2025","unstructured":"Shi K, Zhang G, Xu R, Li XM, Jiang L, Gao Y, et al. Association of body composition with left ventricular remodeling and outcomes in diabetic heart failure with reduced ejection fraction: assessment of sarcopenic obesity using cardiac MRI. Cardiovasc Diabetol. 2025;24(1):79.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2806_CR53","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00424-012-1096-9","volume":"465","author":"JL Grobe","year":"2013","unstructured":"Grobe JL, Rahmouni K, Liu X, Sigmund CD. Metabolic rate regulation by the renin\u2013angiotensin system: brain vs. body. Pflugers Arch Eur J Physiol. 2013;465(1):167\u201375.","journal-title":"Pflugers Arch Eur J Physiol."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02806-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T09:02:49Z","timestamp":1749891769000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02806-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2806"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02806-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.F. is the founder and CEO of Pharmahungary Group, a group of R&D services. There is no conflict of interests on behalf any other author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}